Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Final Guidance For Reporting Adverse Events Gets Serious On Definitions

This article was originally published in The Tan Sheet

Executive Summary

A report of emergency room treatment connected to use of a dietary supplement may not connote a serious adverse event, FDA says in the final guidance on the reporting and recordkeeping of AE information for supplements
Advertisement

Related Content

FDA Says Supplement Adverse Event Under-Reporting Should Feed Growth
Trade Groups Back Matrixx On AER Disclosure In Supreme Court Case
FDA's Readiness Questioned In Electronic AER Comments
FDA Says Supplement AERs Will Be Subject To Lower Threshold Before Action
Supplement AER guidance questioned
Drug, Supplement Industries Need Formal But Timely Guidance - Stakeholders
FDA Needs Information Technology Strategic Plan, GAO Recommends
AER Label Guidance Holds To Requiring Full Addresses For OTCs, Supplements
Adverse Event Collection Expected To Be In Force By Christmas 2007
Adverse Event Collection Expected To Be In Force By Christmas 2007

Topics

Advertisement
UsernamePublicRestriction

Register

PS103130

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel